<DOC>
	<DOCNO>NCT02217800</DOCNO>
	<brief_summary>This study design assess effect different continuous s.c. infusion treatment human growth hormone ( hGH ) level untreated acromegalic patient comparison standard dose octreotide . In addition , pharmacokinetic profile safety tolerability DG3173 continuous s.c. infusion evaluate .</brief_summary>
	<brief_title>The Effect Subcutaneous Infusions 3 Doses DG3173 Growth Hormone Levels Untreated Acromegalics</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Men , woman non childbearing potential , woman childbearing potential either abstain sexual intercourse , sterile partner practice two medically approve , nonhormonal method contraception Diagnosis acromegaly pituitary origin Have ageadjusted insulinlike growth factor type 1 ( IGF1 ) concentration ≥1.2 time upper limit normal range least one measurement 12 month prior screen ( Visit 1 ) AND second raise value screen Have least one random hGH level ≥5 μg/L 12 month prior screen AND second raise value screen Have give write informed consent Ability comply requirement protocol study Previous specific treatment acromegaly 12 month prior screen , include somatostatin analogue ( SSAs ) ; surgery ; radiotherapy pegvisomant Treatment dopamine agonists 3 month prior screen Uncontrolled hypertension Type I diabetes mellitus , poorlycontrolled type II diabetes mellitus ( glycosylated haemoglobin [ HbA1c ] ≥7.5 % ) patient require insulin treatment Gallstones gravel could cause biliary obstruction Hyperprolactinaemia Participation clinical study within 60 day prior screen Receipt blood , blood product plasma derivative 60 day prior screen Body mass index ( BMI ) 22 37 kg/m2 Pregnancy , lactation use hormonal base contraceptive Concomitant intake corticosteroid levodopa A history active alcohol abuse drug addiction Positive viral serology screen result hepatitis B surface antigen , antibody hepatitis C virus , human immunodeficiency virus type 1 2 Evidence suspicion tumour expansion Clinically significant abnormality screen ECG opinion Investigator Any clinically significant abnormal screen laboratory safety test ( biochemistry , haematology dipstick urinalysis ) opinion Investigator Any disease Investigator 's opinion would exclude patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>